Literature DB >> 26058918

Genetic determinants of fetal opiate exposure and risk of neonatal abstinence syndrome: Knowledge deficits and prospects for future research.

T Lewis1,2, J Dinh1, J S Leeder1.   

Abstract

Opiate-dependent pregnant women receive opiate maintenance medications to prevent illicit use and withdrawal. Fetal opiate exposure causes central nervous system (CNS) alterations which manifest as postnatal physical withdrawal. The extensive variability in the Neonatal Abstinence Syndrome phenotype remains unexplained and may be related to variability in fetal exposure and response. Improved understanding of functionally significant genetic variants in pathways influencing placental opiate transfer and fetal response can lead to personalized maternal therapy and optimized neonatal outcomes.
© 2015 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26058918      PMCID: PMC5484056          DOI: 10.1002/cpt.159

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  73 in total

1.  General maternal medication use, folic acid, the MDR1 C3435T polymorphism, and the risk of a child with a congenital heart defect.

Authors:  Sylvia A Obermann-Borst; Aaron Isaacs; Zobia Younes; Ron H N van Schaik; Ilse P van der Heiden; Cornelia M van Duyn; Eric A P Steegers; Régine P M Steegers-Theunissen
Journal:  Am J Obstet Gynecol       Date:  2010-12-22       Impact factor: 8.661

2.  P-glycoprotein expression of the human placenta during pregnancy.

Authors:  S Gil; R Saura; F Forestier; R Farinotti
Journal:  Placenta       Date:  2005 Feb-Mar       Impact factor: 3.481

Review 3.  Complexities of CYP2D6 gene analysis and interpretation.

Authors:  Andrea Gaedigk
Journal:  Int Rev Psychiatry       Date:  2013-10

4.  Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes?

Authors:  Nina Isoherranen; Kenneth E Thummel
Journal:  Drug Metab Dispos       Date:  2013-02       Impact factor: 3.922

Review 5.  Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine.

Authors:  David E Moody
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-03-29       Impact factor: 4.481

6.  In vivo glucuronidation activity of drugs in neonates: extensive interindividual variability despite their young age.

Authors:  Karel Allegaert; Sophie Vanhaesebrouck; Rene Verbesselt; John N van den Anker
Journal:  Ther Drug Monit       Date:  2009-08       Impact factor: 3.681

7.  Prescription drug use among pregnant women in opioid Maintenance Treatment.

Authors:  Ingunn Olea Lund; Svetlana Skurtveit; Anders Engeland; Kari Furu; Edle Ravndal; Marte Handal
Journal:  Addiction       Date:  2012-10-18       Impact factor: 6.526

8.  Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene.

Authors:  Deanna L Kroetz; Christiane Pauli-Magnus; Laura M Hodges; Conrad C Huang; Michiko Kawamoto; Susan J Johns; Doug Stryke; Thomas E Ferrin; Joseph DeYoung; Travis Taylor; Elaine J Carlson; Ira Herskowitz; Kathleen M Giacomini; Andrew G Clark
Journal:  Pharmacogenetics       Date:  2003-08

9.  Modulation of human placental P-glycoprotein expression and activity by MDR1 gene polymorphisms.

Authors:  Sarah J Hemauer; Tatiana N Nanovskaya; Sherif Z Abdel-Rahman; Svetlana L Patrikeeva; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Biochem Pharmacol       Date:  2009-11-06       Impact factor: 5.858

10.  The role of placental breast cancer resistance protein in the efflux of glyburide across the human placenta.

Authors:  E Pollex; A Lubetsky; G Koren
Journal:  Placenta       Date:  2008-06-16       Impact factor: 3.481

View more
  6 in total

1.  Racial differences in opioid withdrawal syndrome among neonates with intrauterine opioid exposure.

Authors:  Massroor Pourcyrous; Mohamad T Elabiad; Divya Rana; Kan P Gaston; Linda DeBaer; Ramasubbareddy Dhanireddy
Journal:  Pediatr Res       Date:  2020-11-19       Impact factor: 3.756

Review 2.  Clinical pharmacology of analgosedatives in neonates: ways to improve their safe and effective use.

Authors:  Anne Smits; John N van den Anker; Karel Allegaert
Journal:  J Pharm Pharmacol       Date:  2016-06-30       Impact factor: 3.765

Review 3.  The Genomics of Neonatal Abstinence Syndrome.

Authors:  F Sessions Cole; Daniel J Wegner; Jonathan M Davis
Journal:  Front Pediatr       Date:  2017-08-22       Impact factor: 3.418

4.  Pharmacogenomic Testing In Pediatrics: Navigating The Ethical, Social, And Legal Challenges.

Authors:  Susanne B Haga
Journal:  Pharmgenomics Pers Med       Date:  2019-10-14

5.  Prenatal opioid-exposed infant extracellular miRNA signature obtained at birth predicts severity of neonatal opioid withdrawal syndrome.

Authors:  Ludmila N Bakhireva; Rajesh C Miranda; Amanda H Mahnke; Melissa H Roberts; Lawrence Leeman; Xingya Ma
Journal:  Sci Rep       Date:  2022-04-08       Impact factor: 4.379

6.  Predictors of neonatal abstinence syndrome in buprenorphine exposed newborn: can cord blood buprenorphine metabolite levels help?

Authors:  Darshan Shah; Stacy Brown; Nick Hagemeier; Shimin Zheng; Amy Kyle; Jason Pryor; Nilesh Dankhara; Piyuesh Singh
Journal:  Springerplus       Date:  2016-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.